CurrentAetnaPolicy 0314

Rituximab (including biosimilars and hyaluronidase formulation)

Clinical coverage, precertification, indications, dosing, continuation criteria, and brand-preference rules for rituximab products for Aetna commercial medical plans.

Policy Summary

PayerAetna

PolicyRituximab (including biosimilars and hyaluronidase formulation)

Policy CodePolicy 0314

Change TypeNo material change

Effective DateJan 4, 1999

Next Review DateJun 27, 2024

Key ActionPrecertification of rituximab (all listed brands/formulations) is required for applicable commercial plan designs.

SourceLink

RequiredPrecert

MultipleProducts listed

ExtensiveOncologic indications

100+Experimental uses

16 wksRA interval floor

Coverage Criteria and Indications

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial approval — Oncologic indications

Covered when ALL of the following are met for oncologic indications:

Primary requirement: Diagnosis of a CD20-positive oncologic disorder confirmed by testing or analysis

See policy section listing CD20-positive malignancies (e.g., NHL subtypes, CLL/SLL, PTLD, primary CNS lymphoma, hairy cell leukemia).

Covered oncologic disorders: Member has one of the enumerated CD20-positive B‑cell malignancies or related conditions (examples include: B-cell ALL; B‑cell lymphomas including DLBCL, follicular lymphoma, mantle cell, marginal zone subtypes, primary mediastinal large B‑cell lymphoma, transformed indolent lymphomas; PTLD; primary cutaneous B‑cell lymphoma; CLL/SLL; hairy cell leukemia; Hodgkin’s nodular lymphocyte‑predominant; pediatric aggressive mature B‑cell lymphomas; Rosai‑Dorfman disease; Waldenström’s macroglobulinemia) as listed in the policy

Full enumeration of eligible oncologic indications is in the policy lists.

Continuation therapy — Oncologic indications

Covered when ALL of the following are met for continuation of therapy:

Continuation for oncologic indications: Member previously authorized for an oncologic indication listed in the initial approval criteria AND there is no evidence of unacceptable toxicity

Continuation consistent with prior authorization and ongoing clinical benefit.

Initial approval — Rheumatoid arthritis

Covered when ALL of the following are met for rheumatoid arthritis (RA):

Combination therapy requirement: Rituximab is to be used in combination with methotrexate or leflunomide unless the member has a documented contraindication or intolerance to these agents

See Appendix for contraindications to MTX/leflunomide.

Prior biologic/targeted therapy: Member has previously received a biologic or targeted synthetic DMARD for RA (e.g., a TNF antagonist or JAK inhibitor) prior to rituximab initiation

Alternative pathway acceptable per policy when biomarker criteria met or prior rituximab exposure documented.

Prior rituximab exposure pathway: Member has received at least two full doses of a listed rituximab product for RA with the most recent dose within 6 months of the request

Applies when rerouting to repeat courses per policy.

Biomarker support pathway: Member has positive rheumatoid factor (RF) or anti‑CCP testing OR has RF, anti‑CCP and CRP and/or ESR results consistent with policy requirements

Biomarker documentation supports diagnosis and treatment appropriateness.

Methotrexate response requirement: Member had inadequate response to an adequate trial of methotrexate (>=15 mg/week for at least 3 months) OR had intolerance/contraindication to methotrexate and inadequate response to another conventional DMARD>=15 mg/week for >=3 months

Documentation of dosing and response required.

Initial approval — Rituxan Hycela

Covered when ALL of the following are met for Rituxan Hycela (subcutaneous formulation):

Prior IV rituximab tolerance: Member has received at least one full dose of a rituximab product by intravenous infusion without severe adverse reaction

Per FDA labeling, Hycela initiation only after prior full IV rituximab dose.

Eligible oncologic indications for Hycela: Member has a CD20-positive oncologic disorder listed for Rituxan Hycela (examples: FL, DLBCL, CLL/SLL, HCL, PTLD, marginal zone lymphomas, primary cutaneous B‑cell lymphoma, Waldenström macroglobulinemia, nodular lymphocyte‑predominant Hodgkin lymphoma)

Rituxan Hycela is not indicated for non‑malignant conditions.

Continuation therapy — Non-oncologic indications

Covered when ALL of the following are met for continuation of non-oncologic indications:

General continuation criteria: Member meets the applicable initial authorization criteria for the non‑oncologic indication and is demonstrating clinical benefit without unacceptable toxicity

For RA continuation, evidence of ≥20% improvement in targeted clinical measures after at least two doses is expected; other indications require documentation of benefit per indication-specific criteria.

Product- and indication-specific dosing (administration criteria)

Appropriate use/dosing when ALL of the following product- and indication-specific conditions are met:

Product-specific administration route: Administer each rituximab product by its approved route: intravenous infusion for reference and biosimilar products (Rituxan, Truxima, Ruxience, Riabni) per prescribing information; Rituxan Hycela is administered subcutaneously only after prior IV rituximab exposure

Do not administer Riabni as an IV push/bolus; follow infusion guidance.

NHL dosing (general): For NHL subtypes, use 375 mg/m2 IV per indication-specific schedules (e.g., once weekly ×4 or ×8 for relapsed/refractory low‑grade/follicular; Day 1 of each chemo cycle for DLBCL; maintenance every 8 weeks as applicable), following product labeling

See individual product prescribing information for exact schedules.

CLL dosing: For CLL in combination with fludarabine/cyclophosphamide (FC): 375 mg/m2 in first cycle then 500 mg/m2 in cycles 2–6 every 28 days per approved regimens

Follow product‑specific instructions (Ruxience/Truxima/Riabni labeling).

Rheumatoid arthritis dosing: Administer two 1,000 mg IV infusions separated by 2 weeks in combination with methotrexate; repeat every 24 weeks or based on clinical evaluation but not sooner than every 16 weeks; recommend methylprednisolone 100 mg IV (or equivalent) 30 minutes prior to each infusion to reduce infusion reactionsno sooner than every 16 weeks

Premedication documentation recommended for RA.

GPA/MPA dosing: Induction dosing: 375 mg/m2 IV once weekly ×4 with glucocorticoids; follow‑up dosing per labeling (e.g., two 500 mg IV infusions separated by 2 weeks then 500 mg IV every 6 months as clinically indicated)

Follow product prescribing information for maintenance schedules.

Zevalin regimen component: When rituximab is used as the unlabeled component of Zevalin regimens, administer 250 mg/m2 as specified in the Zevalin package insert

Follow combined regimen instructions when applicable.

Rituxan Hycela administration specifics: Initiate Hycela only after at least one full IV rituximab dose; administer the labeled subcutaneous dose (1,400 mg or 1,600 mg formulation) into abdominal subcutaneous tissue over the specified minutes with premedication (acetaminophen, antihistamine; consider glucocorticoids) and observe for 15 minutes post‑injectionobserve 15 minutes

Follow vial‑specific volumes and administration times per labeling.

FDA and Compendial Indications

Covered when consistent with FDA-approved indications and accepted compendial uses

Use within FDA‑approved indications: Requested use corresponds to an FDA‑approved indication for the selected rituximab product (e.g., NHL subtypes, previously untreated DLBCL with CHOP, CLL with FC, GPA/MPA in combination with glucocorticoids, RA with methotrexate after TNF antagonist failure, pemphigus vulgaris where applicable)

See FDA‑approved indications in product labeling.

Compendial Uses

Covered when supported by compendia and clinical justification

Compendial use support: Requested off‑label use is supported by recognized compendial sources (e.g., listed compendial uses for rituximab such as autoimmune hemolytic anemia, myasthenia gravis refractory, Sjögren’s, NMOSD) AND treating clinician provides clinical justification and documentation of prior therapies and response

Coverage contingent on compendial citation and clinical rationale.

Coverage for FDA-approved and Compendial Uses

Covered when the request is for FDA-approved indications or recognized compendial uses

Indication and product concordance: The requested rituximab product (reference, biosimilar, or Rituxan Hycela) is being used for an FDA‑approved indication or a compendial use listed in the policy

Biosimilars may be used per demonstrated biosimilarity to the reference product.

Rituxan Hycela specific requirement: For Rituxan Hycela requests, document prior receipt of at least one full IV rituximab dose before initiating subcutaneous Hycela

Hycela not indicated for non‑malignant conditions.

Biosimilar interchange: Coverage applies when biosimilar products are used according to their labeled indications and dosing equivalent to the reference product

Follow biosimilar labeling and HCPCS/CPT coding guidance.

Supported Indications and Contexts

Covered where evidence supports use in specific indications and documented prior therapy/response:

Hairy cell leukemia (relapsed/refractory): Member has relapsed or refractory hairy cell leukemia and has failed at least two courses of cladribine (purine analog) prior to consideration of rituximabfailed >=2 courses of cladribine

Supported by NCI guidance and policy discussion.

Follicular lymphoma — maintenance: Member achieved complete or partial response to rituximab plus chemotherapy induction and is candidate for rituximab maintenance (375 mg/m2 every 8 weeks for 2 years) per PRIMA protocolmaintenance per PRIMA (2 years every 8 weeks)

Improves progression‑free survival; document induction response.

Other hematologic/transplant indications with evidence: Use may be supported for PTLD, selected extranodal CD20+ indolent lymphomas, and refractory/relapsing hematologic contexts when trial evidence or phase II data support benefit and prior therapies/response documenteddisease‑specific

Evidence includes phase II trials and case series; documentation required.

Indication-specific evidence summaries

Evidence-based coverage considerations vary by indication; summarized findings that would inform coverage decisions:

Neuromyelitis optica (NMO): Evidence from prospective cohorts reports marked reduction in relapse rate and clinical stabilization with rituximab when AQP4‑Ab positive and re‑treatment guided by peripheral B‑cell monitoringdocumented AQP4‑Ab positive and relapse history

B‑cell monitoring (eg, CD27+ memory B cells) was used to guide retreatment in cohorts.

Lupus nephritis (Class III/IV): Randomized trial (LUNAR) showed biological activity (B‑cell depletion, serologic changes) but did not meet the primary clinical renal response endpoint at 52 weeks when rituximab was added to MMF and steroids; consider this in coverage decisions and require strong justification if requestedbiopsy‑proven class III/IV LN

LUNAR did not demonstrate superior clinical renal outcomes at 1 year.

Idiopathic membranous nephropathy (IMN): Small studies and meta‑analysis report stabilization or reduction in proteinuria with rituximab in IMN; consider when biopsy‑confirmed disease is refractory or intolerant to other ISTs and documentation providedbiopsy‑confirmed IMN with proteinuria and prior therapy details

Evidence from meta‑analysis suggests comparable effectiveness to other ISTs.

Covered indications with supporting evidence

Covered when ALL of the following are met (examples supported by evidence in document):

Severe cryoglobulinemic vasculitis: Patient has severe mixed cryoglobulinemia/cryoglobulinemic vasculitis with target‑organ involvement (eg, skin ulcers, active glomerulonephritis, or refractory peripheral neuropathy) AND prior antiviral therapy tried if HCV‑associated when appropriate

Supported by randomized trial (De Vita et al) demonstrating superior outcomes with rituximab in severe CV.

Primary Sjögren syndrome with systemic involvement: Patient has primary Sjögren syndrome with systemic extra‑glandular involvement (eg, ESSDAI ≥6) AND inadequate response or intolerance to conventional DMARDs and specialist documentation supporting rituximab useESSDAI ≥6 or equivalent clinical severity

Randomized and prospective data support benefit in systemic pSS contexts.

Not supported indications

Not routinely covered / not supported when ALL of the following apply:

Lupus nephritis — lack of demonstrated clinical benefit: Request for rituximab as induction therapy for Class III/IV lupus nephritis when intended to improve clinical renal outcomes at 1 year, despite LUNAR trial evidence showing no superior clinical benefit

Rovin et al LUNAR trial negative for primary endpoint at 52 weeks.

IgM anti‑MAG demyelinating neuropathy: Use for IgM anti‑MAG demyelinating neuropathy aimed at improving INCAT sensory score is not supported based on randomized trial evidence showing no benefit on the primary outcome at 12 months

Leger et al provided Class I evidence of no benefit on primary endpoint.

Evidence-based coverage considerations

Evidence-based considerations and criteria inferred from presented studies

Anti‑NMDAR encephalitis: Second‑line immunotherapy including rituximab may be used when first‑line treatments (steroids, IVIG, plasmapheresis) fail; observational cohorts show earlier use and second‑line therapy associated with improved outcomesfailure of first‑line immunotherapy

Titulaer et al cohort showed improved odds of good outcome with second‑line therapy (OR 2.69).

IgM anti‑MAG neuropathy evidence summary: Randomized trial demonstrated no improvement in INCAT sensory score at 12 months with rituximab; secondary per‑protocol analyses suggested some benefits on other measures but primary endpoint negative

Class I evidence from Leger et al (RIMAG/RIM trial).

Refractory non‑infectious scleritis: Rituximab may be considered for scleritis refractory to systemic corticosteroids and at least one other systemic immunosuppressant based on phase I/II data showing responses in most treated patientsrefractory to steroids + ≥1 immunosuppressant

Small randomized dose‑ranging trial demonstrated efficacy in 9/12 patients at 24 weeks.

Desensitization and Antibody-Mediated Rejection

Coverage considerations for rituximab in antibody-mediated rejection and desensitization:

Desensitization/AMR criteria: Use may be considered when: (1) patient is highly sensitized as documented by PRA/cPRA (often >50%) or pathogenic donor‑specific antibody (DSA); (2) desensitization is intended to improve transplant compatibility or reduce AMR risk; (3) rituximab is combined appropriately with other desensitization modalities (eg, plasmapheresis, IVIG, bortezomib) per transplant center protocol; (4) risks and limited quality of evidence are documented and individualized transplant center judgment supports therapycPRA often >50%

Evidence heterogeneous; benefit more consistent in acute AMR/desensitization than chronic AMR.

Extra‑nodal lymphoma

Rituximab in rare extra-nodal DLBCL:

Rare extra‑nodal DLBCL consideration: Available observational data indicate poor prognosis for DLBCL at rare extra‑nodal sites and limited evidence of additive survival benefit with rituximab plus CHOP versus CHOP alone; consider case‑by‑case and document expected goals of therapy

Observational series showed no additive survival benefit in reported cohort.

Dermatomyositis

Rituximab in dermatomyositis/amyopathic dermatomyositis:

Dermatomyositis (including anti‑MDA5) consideration: Rituximab may be considered in refractory dermatomyositis or amyopathic dermatomyositis (including anti‑MDA5 cases with rapidly progressive ILD) when standard therapies fail and specialist documents rationale; evidence is primarily case reports/seriesrefractory to standard immunosuppression

Case reports suggest potential benefit in anti‑MDA5 RP‑ILD but randomized data limited.

AS and ocular inflammatory disease

Other inflammatory/autoimmune indications:

AS and ocular inflammatory disease: Rituximab's role in ankylosing spondylitis and certain ocular inflammatory diseases (eg, refractory scleritis) is preliminary; consider only after guideline‑recommended therapies have failed and with specialist oversightfailure/intolerance of guideline therapies

Evidence limited; randomized data lacking for many indications.

ANCA-associated vasculitis (induction and maintenance)

Covered when evidence supports use in ANCA-associated vasculitis

AAV induction or maintenance: Member has a diagnosis of ANCA‑associated vasculitis (GPA, MPA, or renal‑limited AAV) AND either (a) requires induction therapy where cyclophosphamide avoidance is desirable or patient has relapsing disease, OR (b) requires maintenance therapy and is a candidate for rituximab based on prior therapy and relapse risk

Randomized trials (RAVE, MAINRITSAN and follow‑ups) support rituximab for induction and maintenance with improved relapse‑free survival.

Other autoimmune/immune-mediated indications (limited evidence)

Not routinely covered / investigational or limited evidence for other autoimmune indications unless strong justification provided

Anti‑MAG neuropathy: Use for IgM anti‑MAG demyelinating neuropathy is not routinely covered given randomized trial evidence showing no benefit on primary ISS outcome at 12 months

Per Class I evidence from randomized trials.

Aplastic anemia and other limited evidence indications: Rituximab use for aplastic anemia or other conditions without established guideline support is considered investigational unless strong specialty justification and supportive data are provided

Evidence limited or absent in reviews/guidelines.

Anti‑synthetase syndrome/CTD‑ILD: Consider only for refractory ILD associated with anti‑synthetase syndrome or other CTD‑ILD after failure of standard therapies; evidence derived mainly from case series and meta‑analysesrefractory to conventional therapy

Document objective measures (PFTs, imaging) and prior therapy.

Autoimmune blistering dermatoses

Covered with criteria for refractory autoimmune blistering dermatoses

Autoimmune blistering dermatoses: Member has severe or refractory pemphigus or other autoimmune blistering disease AND prior standard therapy (systemic corticosteroids and at least one steroid‑sparing immunosuppressant) has failed, is contraindicated, or member is steroid‑dependent AND treating clinician documents clinical rationale for rituximab use

Observational studies and case series report high complete/partial response rates; reserve for severe/refractory disease.

Covered with criteria — selected autoimmune indications

Covered when ALL of the following are met (per study-supported contexts)

General prerequisites for selected autoimmune indications: Documented diagnosis by biopsy or accepted clinical criteria; specialty evaluation documenting refractory disease or intolerance to guideline first‑line therapies; objective baseline assessments and plan for follow‑up monitoring

See individual condition nodes for specific requirements.

Autoimmune Hepatitis (AIH): Failure or intolerance of corticosteroids and azathioprine documented; consideration as second‑line therapy with dosing regimens per pilot studies (eg, 2 infusions of 1000 mg 2 weeks apart) and monitoring planrefractory to steroids/AZA

Evidence limited to small pilot/retrospective series.

Autoimmune Limbic Encephalitis (ALE): Failure of first‑line immunotherapy (steroids, IVIG, plasmapheresis); rituximab used as second‑line with documented functional impairment and specialist rationale; consider repeated monthly dosing per cohort practicesfailure of first‑line therapy

Retrospective registry data support improved mRS with rituximab.

Autoimmune Myopathies and Myositis: Disease refractory to glucocorticoids and at least one additional immunosuppressive or immunomodulatory agent with documented objective measures (muscle strength, CK) and specialist justification for rituximab userefractory to steroids + ≥1 agent

RIM trial enrolled refractory patients; randomized data mixed but secondary signals observed.

Proposed coverage considerations for off‑label indications

Use considerations derived from the evidence presented in the document:

Off‑label use general considerations: Patient has a qualifying autoimmune/inflammatory diagnosis with limited evidence suggesting potential benefit AND documentation shows failure or intolerance to standard therapies AND treating clinician provides objective measures (eg, ERG for AIR; PFTs for ILD; muscle strength/CK for myositis) AND monitoring and safety plans are specified

Derived from multiple observational studies and systematic reviews; case‑by‑case review recommended.

Dermatomyositis / Polymyositis — evidence-informed coverage considerations

Covered when ALL of the following clinical context and evidence-based considerations apply

Eligibility for dermatomyositis/polymyositis: Definite or probable dermatomyositis or polymyositis with significant disease activity documented by clinical and laboratory measures

Diagnostic features include proximal muscle weakness, elevated CK, EMG or biopsy findings; PFTs when ILD present.

Refractory status required: Disease refractory to glucocorticoids and at least one additional immunosuppressive or immunomodulatory agent (consistent with RIM trial population) with specialist documentationmean prior agents ~3.1 as in RIM trial

RIM enrolled refractory patients; primary endpoint not met but secondary measures suggest benefit.

Baseline and follow‑up assessments: Document baseline core set measures (muscle strength, function, CK) and planned follow‑up assessments to evaluate response over ~44 weeks

Subset analyses in RIM showed sensitivity of core measures and muscle strength to change.

Safety monitoring: Inform patient of infection and infusion reaction risks; plan monitoring for serious AEs and infectious complications

RIM observed 26 serious adverse events, many infections; specialist center management recommended.

Factor VIII/IX inhibitors and Acquired Hemophilia A

Considered for acquired or refractory inhibitor conditions when standard therapy inadequate

Use context for inhibitors: Rituximab may be used for acquired hemophilia A or for inhibitor eradication in selected cases when standard immunosuppression has failed or is contraindicated

No randomized trials for acquired hemophilia A; evidence from registries and case series supports use in resistant cases.

Documentation requirement: Document failure of first‑line immunosuppression (eg, steroids ± cyclophosphamide) or contraindication to such therapies and rationale for rituximab use

EACH2 and systematic reviews indicate variable remission rates; case‑by‑case assessment needed.

Fibrosing mediastinitis / IgG4-related disease and progressive FM

May be considered in select fibro-inflammatory conditions with supportive histopathology or refractory progressive disease

Histopathology‑guided use in IgG4‑related disease: Consider rituximab when tissue demonstrates IgG4‑related disease features or when disease is progressive and refractory to glucocorticoids and steroid‑sparing agents

Systematic reviews and case series report high remission rates but relapse and AE rates vary.

Concurrent management: When used, rituximab is often combined with a short prednisone taper and prophylaxis as indicated; document histopathology and center experience

Case reports included prophylaxis for opportunistic infections during B‑cell depletion.

Idiopathic Membranous Nephropathy (IMN)

Evidence-supported role in nephrotic syndromes

Idiopathic membranous nephropathy (IMN): Consider rituximab for biopsy‑confirmed IMN in patients who are refractory to or intolerant of other immunosuppressive therapies, with documented proteinuria and treatment rationale

Meta‑analysis shows comparable effectiveness to other ISTs and steroid‑sparing benefits.

Immune Thrombocytopenic Purpura

Second-line use in immune thrombocytopenic purpura (ITP)

ITP indication: Rituximab may be considered for chronic or refractory ITP or as a splenectomy‑sparing option when standard therapies fail; document bleeding symptoms, prior therapies and response

Pediatric and adult series show measurable response rates; conservative use in children recommended pending more data.

Pediatric caution: In pediatric ITP, reserve rituximab for patients who have failed splenectomy or when other options exhausted; provide specialist justification and monitoring plan

Pooled pediatric data show response but recurrence and safety considerations warrant cautious use.

Multiple Sclerosis (RRMS and PPMS)

Evidence summary for Multiple Sclerosis — efficacy and limitations

RRMS evidence: Small randomized trials demonstrate reduction in MRI gadolinium‑enhancing lesions and relapse rates short‑term (up to 48 weeks) with rituximab; long‑term disability and safety data limited

Phase II RCT (n=104) showed reduced lesions and relapses up to 48 weeks.

PPMS evidence: Large randomized trial in PPMS did not meet its primary endpoint for time to confirmed disease progression; subgroup signals exploratory only and do not support routine PPMS use

Phase II/III PPMS trial failed primary endpoint; routine coverage not supported.

Myasthenia Gravis (refractory, MuSK and AChR subtypes)

Evidence summary for Myasthenia Gravis (MG)

Refractory MG: Rituximab is used for refractory MG and is associated in observational studies and meta‑analyses with clinical improvement and steroid‑sparing effects, particularly in MuSK‑positive patients; randomized data are limitedrefractory to standard immunosuppressants or IVIG

Meta‑analysis reports ~64% achieving minimal manifestation status or better; safety profile acceptable with monitoring.

Documentation and monitoring: Document prior therapies and failures, antibody subtype (MuSK vs AChR), clinical response measures, and plan for ongoing monitoring and safety management

Specialist documentation recommended; data largely observational.

For rheumatoid arthritis (RA) requests, Aetna requires documentation that the planned administration is not scheduled sooner than 16 weeks from the last rituximab dose and that rituximab will not be used concurrently with other biologic disease‑modifying antirheumatic drugs. Prescribers should be appropriate specialists (eg, rheumatologist) and provide evidence of prior trials (or intolerance/contraindication) of methotrexate or other conventional DMARDs per the policy criteria. Continuation authorizations for RA should document clinical benefit and absence of unacceptable toxicity.

Riabni (rituximab‑arrx) is supplied for intravenous infusion only; it must not be administered as an IV push or bolus. Single‑dose vials are intended for infusion by a healthcare professional per the product instructions.

Use of rituximab for indications explicitly listed in the policy as experimental, investigational, or unproven (extensive list in the CPB) is not supported. Examples enumerated in the policy include, but are not limited to, acquired hemophilia A, anti‑MAG neuropathy, intrathecal administration for progressive MS, amyopathic dermatomyositis, ankylosing spondylitis, anterior nodular scleritis, autoimmune encephalitis, autoimmune hepatitis, and many other conditions specified in the document.

Per FDA‑approved labeling, Rituxan Hycela (subcutaneous rituximab with hyaluronidase) is intended for use in malignancies and is not indicated for non‑malignant conditions. Initiation of Rituxan Hycela is permitted only after at least one full intravenous dose of a rituximab product has been administered.

Rituximab is not established as routine therapy for multiple myeloma or plasma cell leukemia; authoritative reviews and compendia (eg, UpToDate, NCCN compendia) do not list rituximab as a recommended standard therapy for these conditions.

Graves' orbitopathy (thyroid eye disease) and many pediatric autoimmune conditions have limited and inconsistent evidence; the policy describes rituximab use in these settings as experimental or insufficiently studied, and randomized trials are needed to establish efficacy and safety.

Available evidence does not demonstrate a convincing benefit of rituximab for bronchiolitis obliterans following allogeneic hematopoietic stem cell transplantation; rituximab is not supported for this indication in the policy.

A Cochrane review identified no randomized clinical trials of rituximab for acquired hemophilia A, so high‑quality RCT evidence is lacking and the indication is considered investigational in the absence of trial‑level data.

The policy notes that evidence for rituximab in chronic antibody‑mediated renal allograft rejection (CAMR) is heterogeneous and does not reliably support benefit; while some studies in acute AMR/desensitization report improvements, CAMR studies more often show no effect or inconsistent results.

Routine use of rituximab for IgM anti‑MAG demyelinating neuropathy is excluded based on randomized trial evidence (RIMAG/RIM) showing no improvement in the primary INCAT sensory score at 12 months; primary outcome results do not support routine coverage.

Rituximab is not supported as first‑line therapy for inflammatory myositis; the largest randomized trial (RIM) did not meet its primary efficacy endpoint, so use is generally reserved for refractory cases and considered with caution.

Clinical practice guidelines and major reviews (KDIGO, Japanese Society of Pediatric Nephrology, UpToDate) do not list rituximab as a therapeutic option for crescentic IgA nephropathy, indicating lack of guideline support for this indication.

Rituximab is not established as a standard therapy for hypersensitivity pneumonitis and is not listed for routine treatment of pulmonary hypertension in major reviews; such uses are considered experimental or case‑by‑case.

Systemic lupus erythematosus (SLE) is not an FDA‑approved indication for rituximab; randomized trials (eg, EXPLORER, LUNAR) failed primary endpoints and the product labeling includes reports of progressive multifocal leukoencephalopathy (PML), which are noted as important safety considerations.

Primary‑progressive multiple sclerosis (PPMS) is not supported by randomized trial evidence meeting primary endpoints; Phase II/III trials did not demonstrate a clear benefit, so rituximab is not recommended for routine PPMS therapy.

All hematologic and oncologic indications not specifically listed as medically necessary in the policy are considered experimental, investigational, or unproven and therefore excluded from routine coverage unless otherwise specified or supported by compendia.

Initiating a patient on Rituxan Hycela without documentation of at least one prior full intravenous rituximab dose is inconsistent with FDA labeling and the policy; prior IV administration must be documented before subcutaneous Hycela is authorized.

Anti‑chimeric antibody testing (immunoassays for anti‑chimeric antibodies) is considered experimental, investigational, or unproven for guiding rituximab therapy due to insufficient evidence in the peer‑reviewed literature.

Intrathecal administration of rituximab for progressive multiple sclerosis is classified as experimental, investigational, or unproven because effectiveness has not been established in clinical trials.

Routine use of rituximab in multiple myeloma and plasma cell leukemia is not supported by major clinical reviews and compendia and therefore is not considered a standard, evidence‑based indication.

The LUNAR randomized, double‑blind, placebo‑controlled phase 3 trial found that adding rituximab to mycophenolate mofetil and corticosteroids for Class III/IV lupus nephritis did not improve clinical renal outcomes at 1 year despite biologic activity (B‑cell depletion and serologic changes); this negative primary outcome informs the policy’s noncoverage stance for routine use in that setting.

Randomized trial evidence does not support rituximab for induction of lupus nephritis (no improved renal outcomes in LUNAR) and for IgM anti‑MAG demyelinating neuropathy (no improvement in primary INCAT sensory score), leading to these indications being considered not medically necessary based on available RCT data.

The RIM/RIMAG randomized trial in IgM anti‑MAG demyelinating neuropathy failed to demonstrate benefit on the primary outcome (INCAT sensory score at 12 months), and the policy therefore concludes that rituximab is not supported by primary outcome benefit for this indication.

Class I randomized evidence from the RIM/RIMAG trial shows rituximab did not improve the INCAT sensory score in IgM anti‑MAG neuropathy at 12 months; accordingly, rituximab is not medically necessary for improving this primary outcome measure.

Rituximab is not considered medically necessary as routine therapy for autoimmune diseases where standard therapies are effective (for example, autoimmune hepatitis responsive to steroids and azathioprine) or where high‑quality randomized evidence is lacking; such uses should be reserved for refractory cases or clinical trials.

For chronic spontaneous urticaria and collagenous gastritis (and related CMV gastritis complications), the evidence for rituximab is primarily limited to case reports and small series; these indications lack randomized controlled trial support and are therefore considered experimental or of insufficient evidence for routine coverage.

Eradication of factor VIII/IX inhibitors in inherited hemophilia and treatment of acquired hemophilia lack randomized clinical trial evidence; routine use of rituximab for inhibitor eradication is not supported by RCT data and may be considered not medically necessary absent stronger evidence.

Primary‑progressive multiple sclerosis (PPMS) is not supported by Phase II/III randomized trial evidence meeting primary endpoints; trials failed to show a clear benefit and the policy reflects that lack of demonstrated efficacy for routine PPMS treatment.

Billing Codes and Administration Details

HCPCS and related CPT codesmixed

62350	Implantation, revision or repositioning of tunneled intrathecal or epidural catheter; without laminectomy.
62351	Implantation, revision or repositioning of tunneled intrathecal or epidural catheter; with laminectomy.
83520	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified [anti-chimeric antibody testing].
96450	Chemotherapy administration, into CNS (eg, intrathecal), requiring and including spinal puncture.
J9312	Injection, rituximab, 10 mg.
Q5115	Injection, rituximab-abbs, biosimilar, (Truxima), 10 mg.
Q5119	Injection, rituximab-pvvr, biosimilar, (RUXIENCE), 10 mg.
Q5123	Injection, rituximab-arrx, biosimilar, (riabni), 10 mg.
J9311	Injection, rituximab 10 mg and hyaluronidase.

Other CPT codes related to CPBCPT

96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular.
96401	Chemotherapy administration, subcutaneous or intramuscular.
96402	Chemotherapy administration, subcutaneous or intramuscular.

ICD-10 codes covered if selection criteria are metICD-10Covered

C82.00 - C82.99	Follicular lymphoma.
C83.30 - C83.39	Diffuse large B-cell lymphoma.
C91.10 - C91.12	Chronic lymphocytic leukemia of B-cell type.
D47.Z1	Post-transplant lymphoproliferative disorder (PTLD).
M05.00 - M14.89	Rheumatoid arthritis and other inflammatory polyarthropathies.
G35	Multiple sclerosis.
G36.0	Neuromyelitis optica.

ICD-10 codes not covered for indications listed in CPBICD-10Not Covered

A87.0 - A87.9	Viral meningitis.
C74.00 - C74.92	Malignant neoplasm of adrenal gland.
C90.10 - C90.12	Plasma cell leukemia.

inv-63: Riabni retreatment interval

Riabni retreatment intervalSubsequent courses every 24 weeks or based on clinical evaluation, but not sooner than every 16 weeks.

Recommended premedicationGlucocorticoids (eg, methylprednisolone 100 mg IV or equivalent) 30 minutes prior to each infusion to reduce infusion reactions.

Concomitant therapyRiabni given in combination with methotrexate for rheumatoid arthritis indications.

inv-64: Rituxan Hycela observation time

Post-administration observationObserve 15 minutes following administration.

PremedicationPremedicate with acetaminophen and an antihistamine; consider glucocorticoids per labeling.

Administration site and volumeAdminister specified volume into abdominal subcutaneous tissue (11.7 mL for 1,400 mg; 13.4 mL for 1,600 mg) over ~5–7 minutes.

inv-65: cPRA threshold commonly considered for desensitization

cPRA threshold for desensitization considerationCalculated PRA (cPRA) commonly considered > 50% when desensitization is contemplated.

Desensitization modalitiesDesensitization strategies may include plasmapheresis, IVIG, rituximab, and bortezomib as part of individualized transplant center protocols.

Evidence qualityEvidence for desensitization approaches is heterogeneous and largely based on small observational studies; individualized judgment required.

Prior Authorization, Documentation, and Step-Therapy Requirements

Prior Authorization

Precertification Required

Precertification of all rituximab products (Rituxan, Truxima, Riabni, Ruxience, Rituxan Hycela) is required for Aetna participating providers and members in applicable plan designs. Failure to obtain precertification may result in denial. For precertification and Statement of Medical Necessity (SMN) forms, contact Aetna Specialty Pharmacy Precertification (phone: 866-752-7021; fax: 888-267-3277).

Precertification required for Rituxan, Truxima, Riabni, Ruxience, Rituxan Hycela
SMN/precertification contact: 866-752-7021; fax: 888-267-3277

Prior Authorization

Prior Authorization and Product/ Dose Documentation

Prior authorization is required for rituximab products and listed HCPCS codes (e.g., J9312; Q5115, Q5119, Q5123). Prior authorization requests must specify the exact product/formulation, the clinical indication, and indication-specific dosing schedule (for example: NHL 375 mg/m2 weekly ×4 or maintenance 375 mg/m2 every 8 weeks). For Rituxan Hycela, prior authorization must confirm that at least one full IV rituximab dose was administered before subcutaneous initiation.

Required HCPCS: J9312, Q5115 (Truxima), Q5119 (Ruxience), Q5123 (Riabni)
Requests must include product, formulation, indication, and dosing schedule
Rituxan Hycela initiation requires documentation of prior full IV rituximab dose

Documentation Required

Clinical Documentation Required

Documentation expectations vary by indication. For autoimmune and inflammatory conditions, prior authorization should include detailed clinical documentation of diagnosis, disease severity, prior lines of therapy and responses or intolerances, and rationale for rituximab use (including why standard/guideline-recommended therapies failed or are inappropriate). For transplant desensitization or antibody‑mediated rejection (AMR), provide cPRA, transplant-center justification, prior desensitization interventions (plasmapheresis, IVIG, bortezomib), and intent (pre-transplant desensitization vs treatment of AMR).

Autoimmune indications: diagnosis, severity, prior therapies tried, objective measures where available (e.g., biopsy, antibody testing, imaging), and treatment response
Transplant/desensitization: cPRA, prior plasmapheresis/IVIG/bortezomib, transplant center justification, intended goal (reduce PRA, enable transplant, treat AMR)

Denial Risk

Evidence, Denial Risks, and Maintenance/Labeling Limits

Evidence limitations and denial risks: many off-label autoimmune and neurologic uses lack high-quality randomized controlled trial (RCT) evidence. Examples with negative or inconclusive RCTs (LUNAR for lupus nephritis; PRIM A/RIM for myositis; RIMAG/anti‑MAG neuropathy) may require strong justification and specialty‑center management. Requests for indications considered experimental/investigational (see policy list) may be denied. Rituxan Hycela is not indicated for non-malignant conditions and initiation without prior IV dosing is contrary to FDA labeling and may be denied.

SLE/lupus nephritis: LUNAR negative primary outcome — detailed justification likely required
Dermatomyositis/myositis: RIM did not meet primary endpoint — potential denial risk for myositis indications without strong supporting data
Anti‑MAG neuropathy: RCTs failed primary outcome — limited benefit; may be denied
Rituxan Hycela: initiation requires prior IV dose; not indicated for non-malignant conditions

Step Therapy

Brand Preference and Step‑Therapy Expectations

Step therapy and brand‑preference guidance: Truxima (rituximab‑abbs) is the preferred CD20 biosimilar; other brands may be considered if patient has contraindication, intolerance, or inadequate response to Truxima. Rituxan Hycela (subcutaneous) may be authorized only after documentation of at least one full IV rituximab dose. For RA, rituximab is generally used in combination with methotrexate after inadequate response to TNF antagonists. For autoimmune and neurologic indications, require trials of guideline-recommended first-line therapies (e.g., corticosteroids, IVIG, plasmapheresis, conventional immunosuppressants) before rituximab, except where evidence or clinical judgment supports earlier use (e.g., severe refractory disease, contraindication to alternatives).

Preferred product: Truxima (rituximab‑abbs)
Riabni/Rituxan/Ruxience/Rituxan Hycela considered if Truxima contraindicated/intolerant/ineffective
Rituxan Hycela subcutaneous requires prior IV rituximab dose documentation
RA: use after inadequate response to TNF antagonists and with methotrexate
Require documented trial of first-line agents (steroids, IVIG, plasmapheresis, immunosuppressants) prior to rituximab for many indications

Documentation Required

Monitoring, Retreatment, and Maintenance Documentation

Monitoring and retreatment notes: for certain indications (e.g., neuromyelitis optica), serial peripheral B‑cell counts and relapse history may guide retreatment timing and should be included in requests for maintenance/retreatment. For maintenance therapy or ongoing retreatment requests, document objective response to prior rituximab courses; lack of documentation of benefit increases risk of denial.

NMO retreatment: include serial peripheral B‑cell (CD19/CD27) counts and clinical relapse history
Maintenance therapy: provide objective evidence of prior benefit and timing of prior doses
Prior IV dose documentation: required for Rituxan Hycela and should include date and dose of prior IV rituximab

Dosing Schedules and Regimens

Indication	Regimen / Dose	Coverage
Chronic lymphocytic leukemia (CLL) — in combination with fludarabine and cyclophosphamide (FC)	Rituximab 375 mg/m2 IV in the first cycle; 500 mg/m2 IV in cycles 2–6, given every 28 days (with fludarabine and cyclophosphamide)	Covered

Indication	Regimen / Dose (typical)	Coverage
Non‑Hodgkin’s lymphoma (NHL) — various subtypes	Rituximab 375 mg/m2 IV per prescribing schedules: e.g., once weekly x4 or x8 for relapsed/refractory low‑grade/follicular; Day 1 of chemo cycles for DLBCL (up to 8 doses); maintenance single‑agent every 8 weeks as indicated	Covered

Indication	Regimen / Dose	Coverage
Pemphigus vulgaris (PV)	Two 1,000 mg IV infusions separated by 2 weeks (induction), then 500 mg IV at Month 12 and every 6 months thereafter or based on clinical evaluation; dose upon relapse: 1,000 mg IV; subsequent infusions no sooner than 16 weeks	Covered
Rheumatoid arthritis (RA)	Two 1,000 mg IV infusions separated by 2 weeks in combination with methotrexate; repeat courses every 24 weeks or based on clinical evaluation but not sooner than every 16 weeks; methylprednisolone 100 mg IV (or equivalent) recommended 30 minutes prior to each infusion	Covered

Product	Administration requirements / Procedure	Coverage
Rituxan Hycela (rituximab + hyaluronidase) — subcutaneous formulation	Initiate only after the patient has received at least one full IV dose of a rituximab product without severe adverse reactions; administer specified subcutaneous dose (1,400 mg/11.7 mL or 1,600 mg/13.4 mL) into abdominal subcutaneous tissue over ~5–7 minutes; premedicate with acetaminophen and antihistamine (consider glucocorticoids); observe for 15 minutes post‑injection	covered (when IV tolerance and labeled oncologic indication met)

Context	Rituximab component dose	Coverage
Rituximab as the unlabelled component of the Zevalin (ibritumomab tiuxetan) therapeutic regimen for NHL	Rituximab 250 mg/m2 IV per the Zevalin package insert (refer to Zevalin labeling for full regimen)	Covered

Indication	Regimen / Dose (example schedules)	Coverage
Non‑Hodgkin’s lymphoma (NHL) — subtypes including follicular and DLBCL	Rituximab 375 mg/m2 IV per indication‑specific schedules: weekly x4 or x8 for relapsed/refractory low‑grade/follicular; Day 1 of chemotherapy cycles for DLBCL (up to 8 infusions); single‑agent maintenance every 8 weeks where applicable	Covered

Product (Riabni)	Regimen / Dose	Coverage
Riabni (rituximab-arrx) for rheumatoid arthritis (in combination with methotrexate)	Two 1,000 mg IV infusions separated by 2 weeks; glucocorticoid premedication (eg, methylprednisolone 100 mg IV 30 minutes prior) recommended; repeat courses every 24 weeks or based on clinical evaluation but not sooner than every 16 weeks	Covered

Product	Administration specifics	Coverage
Rituxan Hycela (subcutaneous) — administration specifics	Administer after prior full IV rituximab dose; premedicate with acetaminophen and antihistamine and consider glucocorticoids; inject specified subcutaneous volume into abdominal tissue over ~5–7 minutes (11.7 mL for 1,400 mg; 13.4 mL for 1,600 mg) and observe patient for 15 minutes following administration	covered when labeling prerequisites met

Indication / Use	Rituximab dose	Coverage
Diffuse large B‑cell lymphoma (DLBCL) — in combination with CHOP or other anthracycline‑based chemotherapy	Rituximab 375 mg/m2 IV administered on Day 1 of each chemotherapy cycle (per prescribing information) as part of R‑CHOP or similar regimens	Covered

Indication	Regimen / Dose	Coverage
Follicular lymphoma — single‑agent, combination induction, and maintenance	Single‑agent relapsed/refractory: rituximab 375 mg/m2 IV weekly x4 (or per label). Previously untreated in combination with chemotherapy: rituximab 375 mg/m2 IV on Day 1 of each chemo cycle (up to 8 doses). Maintenance (PRIMA): rituximab 375 mg/m2 IV every 8 weeks for 2 years (12 doses)	Covered

Indication	Regimen / Dose	Coverage
Chronic lymphocytic leukemia (CLL) — combination with fludarabine and cyclophosphamide (FC)	Rituximab given with FC per CLL regimen: 375 mg/m2 IV in cycle 1, then 500 mg/m2 IV in cycles 2–6 every 28 days	Covered

Indication	Regimen / Dose	Coverage
Follicular lymphoma — maintenance therapy after response to induction immunochemotherapy	Rituximab 375 mg/m2 IV every 8 weeks for 2 years (PRIMA protocol)	Covered

Indication	Regimen / Dose	Coverage
Post‑transplant lymphoproliferative disorder (PTLD)	Rituximab 375 mg/m2 IV once weekly for 4 weeks (as used in cited phase II trial)	Covered

Indication / Setting	Regimen / Dose (pilot study)	Coverage
Conjunctival / extranodal indolent lymphomas — intralesional administration (investigational)	Pilot dosing: 4 weekly intralesional injections followed by monthly injections (per pilot study); protocols varied and evidence preliminary	Experimental

Context	Finding	Coverage implication
DLBCL involving rare extra‑nodal sites (adrenal gland, ovary, pancreas, uterus, esophagus, prostate)	In a series of 39 DLBCL patients at rare extra‑nodal sites, rituximab plus CHOP did not provide additive survival benefit over CHOP alone; median OS was poor	mixed (case‑by‑case consideration)

Context	Finding	Coverage implication
DLBCL at rare extra‑nodal sites — analysis of outcomes	Rituximab plus CHOP showed no additive survival benefit over CHOP alone in the cited cohort of patients with rare extra‑nodal DLBCL	mixed

Context	Regimen noted	Evidence level / Coverage
Case report: small lymphocytic lymphoma (SLL) in a patient with CREST syndrome	FCR regimen (fludarabine/cyclophosphamide/rituximab) described in single case report	covered (single‑case evidence only; use per clinical context)

Recommended Line of Therapy

first-line | second-line

Line of therapy context: first‑line | second‑line where applicable

NHL line examples: Rituximab may be used as first‑line in combination with chemotherapy (Day 1 of cycles for DLBCL, previously untreated follicular) and as single‑agent for relapsed/refractory follicular lymphoma (weekly ×4 or ×8), with maintenance as indicated

Schedules vary by subtype per product labeling.

second-line

Line of therapy context: second‑line examples

CLL regimen context: Rituximab used in combination with fludarabine and cyclophosphamide (FC) per CLL regimens (375 mg/m2 first cycle then 500 mg/m2 cycles 2–6), representing a labeled regimen in certain settings

Indication/regimen per product labeling.

first-line

Line of therapy context: first‑line examples

CLL first‑line labeling: Rituximab in combination with FC included among FDA‑approved options for previously untreated and previously treated CLL

Follow prescribing information for dosing.

first-line

Line of therapy context: first‑line examples

Follicular lymphoma first‑line: Rituximab in combination with first‑line chemotherapy for previously untreated follicular lymphoma and as maintenance for responders per labeling

PRIMA maintenance protocol referenced.

first-line | second-line

Line of therapy context: first‑line | second‑line where applicable

Line‑specific examples: Rituximab used across lines: single‑agent in relapsed/refractory follicular lymphoma; part of first‑line chemo (eg, CHOP for DLBCL); combined regimens for CLL; maintenance therapy where indicated

Refer to product‑specific prescribing schedules.

first-line

Line of therapy context: first‑line examples

Follicular lymphoma maintenance: After response to rituximab‑plus‑chemotherapy induction, maintenance rituximab (375 mg/m2 every 8 weeks for 2 years) is an evidence‑supported first‑line maintenance strategymaintenance per PRIMA

Document response to induction prior to maintenance.

salvage

Line of therapy context: salvage

Hairy cell leukemia salvage: Rituximab considered in relapsed/refractory hairy cell leukemia after failure of at least two courses of cladribine (salvage context)failed >=2 cladribine courses

NCI guidance and policy discussion support this sequencing.

Required Biomarkers and Tests

inv-165: CD20 — Biomarker requirement

Biomarker requirementDocumented expression of CD20 is required for many oncologic indications of rituximab.

Cell types expressing CD20CD20 is expressed on pre-B and mature B lymphocytes and on >90% of B‑cell non-Hodgkin lymphomas.

Testing confirmationCD20-positivity should be confirmed by appropriate testing or pathology report prior to therapy in oncologic indications.

inv-166: CD20 — Expression present on malignant cells (documented)

CD20 expression on malignant cellsPolicy requires documented expression of CD20 on malignant cells for many oncologic indications.

Relevance to hairy cell leukemiaRituximab may be used for relapsed/refractory hairy cell leukemia where prior purine-analog therapy failed; CD20 expression informs use.

Use in B-cell lymphomasCD20 expression is the principal determinant for rituximab use across diverse B‑cell lymphoma subtypes listed in the policy.

inv-167: MDA5 — Biomarker reference for MDA5-associated dermatomyositis contexts

MDA5 biomarker contextMDA5 (anti‑MDA5) is referenced as a biomarker for selection/discussion in anti‑MDA5–associated dermatomyositis contexts (not a CD20 marker).

Clinical significanceAnti‑MDA5–positive dermatomyositis is frequently amyopathic and associated with rapidly progressive ILD and poor prognosis; case reports note rituximab responses.

Role in decision-makingPresence of anti‑MDA5 antibodies may inform consideration of rituximab in refractory cases with pulmonary involvement based on limited evidence.

Terms and Condition Definitions

inv-129: BACKGROUND — Rituximab description and general scope (fallback to document for full background)

Rituximab descriptionRituximab is a genetically engineered chimeric mouse/human monoclonal antibody directed against the CD20 antigen on B lymphocytes.

Scope of useUsed for a wide range of B‑cell hematologic malignancies and various autoimmune conditions; dosing and schedules vary by indication.

Hyaluronidase co-formulationA hyaluronidase‑facilitated subcutaneous formulation (Rituxan Hycela) is available for patients who have tolerated IV rituximab.

inv-130: CD20-positive — Tumors or cells expressing CD20 antigen

Definition of CD20-positive tumors/cellsTumors or cells expressing the CD20 antigen as confirmed by testing or analysis; required for many oncologic indications in this policy.

Testing requirementCD20-positivity should be documented in pathology or testing reports prior to rituximab use for oncologic indications.

Clinical relevanceCD20 expression underlies rituximab’s mechanism of action and eligibility for many B‑cell malignancy indications listed by the policy.

inv-131: NHL dosing (rituximab) — Standard IV dose commonly 375 mg/m2 with schedules varying by subtype and line.

Standard NHL IV doseCommon IV dose for NHL is 375 mg/m2, administered per indication-specific schedules (eg, weekly ×4 or ×8 for relapsed/refractory; Day 1 of chemo cycles for DLBCL).

Retreatment and maintenanceRetreatment schedules include once-weekly courses for relapse; maintenance may be given every 8 weeks as applicable per indication.

Schedule varies by subtypeNumber and timing of doses depend on NHL subtype and treatment intent (induction, consolidation, maintenance) per prescribing information.

inv-132: Rituxan Hycela — Subcutaneous formulation requiring prior IV exposure

Rituxan Hycela formulationRituxan Hycela is a subcutaneous co-formulation of rituximab and hyaluronidase for subcutaneous injection after prior IV rituximab exposure.

Initiation prerequisitePer FDA labeling, initiate Rituxan Hycela only after the patient has received at least one full IV dose of a rituximab product without severe adverse reactions.

Indication limitationRituxan Hycela dosing and indications mirror specific CD20-positive oncologic disorders; not indicated for non-malignant conditions per labeling.

inv-133: Rituxan Hycela — Subcutaneous co-formulation of rituximab and hyaluronidase; label limits.

Co-formulation detailsRituxan Hycela is a subcutaneous co-formulation of rituximab and hyaluronidase available as 1,400 mg/11.7 mL and 1,600 mg/13.4 mL single-dose vials.

Administration procedureAdminister specified vial volume into abdominal subcutaneous tissue over ~5–7 minutes with premedication and observe for 15 minutes post-dose.

Label limitsInitiation is limited to patients who have tolerated a prior full IV rituximab dose; labeled warnings include PML, HBV reactivation, and severe mucocutaneous reactions.

inv-134: CD20 — Antigen description and relevance

CD20 antigen descriptionCD20 is a transmembrane antigen on pre-B and mature B lymphocytes and on >90% of B‑cell non‑Hodgkin lymphomas; it is the target of rituximab-mediated cytotoxicity.

Mechanism relevanceBinding to CD20 mediates B-cell lysis via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and induction of apoptosis.

Clinical implicationDetection of CD20 on malignant cells informs eligibility for rituximab therapy across oncologic indications in the policy.

inv-135: Rituxan Hycela limitation — Must be initiated only after at least one full IV dose; not indicated for non-malignant conditions.

Initiation requirement for HycelaRituxan Hycela must be initiated only after at least one full IV dose of an intravenous rituximab product has been administered without severe reaction.

Non-malignant indication restrictionRituxan Hycela is not indicated for the treatment of non-malignant conditions per labeling.

Documentation neededPrior IV rituximab exposure and tolerance should be documented when requesting subcutaneous Hycela for authorization.

inv-136: Maintenance therapy (follicular lymphoma) — Continuation definition per PRIMA

Maintenance definition (PRIMA)Maintenance therapy in follicular lymphoma per PRIMA: rituximab 375 mg/m2 every 8 weeks for 2 years following response to induction therapy.

Benefit and risksPRIMA showed improved progression-free survival with maintenance rituximab but with increased grade 3–4 adverse events and infections.

EligibilityMaintenance is for patients who achieved complete or partial response to rituximab-plus-chemotherapy induction.

inv-137: Relapsed/refractory hairy cell leukemia criteria — Failed at least two courses of cladribine before rituximab considered

Hairy cell leukemia refractory criteriaRelapsed/refractory hairy cell leukemia considered for rituximab after failure of at least two courses of cladribine (purine analog therapy).

Evidence noteNCI guidance and observational studies support rituximab use in relapsed HCL though single-agent activity is modest in cladribine-failed patients.

Treatment expectationRituximab can induce durable remissions in relapsing HCL but evidence size is limited; document prior purine-analog therapy.

inv-138: NMO / AQP4-Ab testing — AQP4-Ab testing essential for NMO diagnosis

AQP4‑Ab testing requirementAquaporin‑4 antibody (AQP4‑Ab or NMO‑IgG) testing is essential for the diagnosis of neuromyelitis optica (NMO) and guides therapy selection.

Monitoring for retreatmentSerial peripheral B‑cell monitoring (eg, CD27+ memory B cells) and clinical relapse history have been used to guide re‑treatment in cohort studies.

Therapy roleRituximab is increasingly regarded as an established therapy for NMO in cohort evidence when AQP4‑Ab positive.

inv-139: LUNAR trial — Phase 3 trial description for lupus nephritis context

LUNAR trial descriptionLUNAR was a randomized, double-blind, placebo-controlled phase 3 trial evaluating rituximab plus mycophenolate mofetil and corticosteroids versus placebo plus MMF and steroids in Class III/IV lupus nephritis (N = 144).

Primary outcome resultRituximab did not achieve superior clinical renal response at 52 weeks despite biologic effects (B‑cell depletion, serologic improvements).

Safety findingsRates of serious adverse events were similar between groups though neutropenia, leukopenia, and hypotension were more frequent with rituximab.

inv-140: Severe cryoglobulinemic vasculitis (CV) — Definition including organ involvement per De Vita et al.

Severe CV definitionSevere cryoglobulinemic vasculitis (CV) includes target organ involvement such as skin ulcers, active glomerulonephritis, or refractory peripheral neuropathy as used in De Vita et al.'s randomized trial.

Evidence of benefitDe Vita et al. randomized trial showed superior treatment survival and disease activity reduction with rituximab versus conventional therapy in severe CV.

Treatment regimen notedRTX group received 2 infusions of 1 g each with glucocorticoid lowering when possible; second course at relapse was part of study design.

inv-141: IgM anti‑MAG demyelinating neuropathy — Definition and relation to studied regimen

IgM anti‑MAG neuropathy definitionIgM anti‑MAG demyelinating neuropathy is associated with IgM antibodies against myelin‑associated glycoprotein and was studied with rituximab 375 mg/m2 regimens.

Trial outcomeRandomized trials (eg, Leger et al.) provided Class I evidence showing no improvement in the INCAT sensory score at 12 months with rituximab.

Evidence nuancePer‑protocol analyses suggested improvements in some secondary outcomes, but primary endpoint was negative; routine use is not supported by RCT primary outcome.

inv-142: Anti‑NMDAR encephalitis — Definition and typical presentation

Anti‑NMDAR encephalitis definitionAnti‑NMDAR encephalitis is an autoantibody-mediated encephalitis characterized by memory deficits, seizures, and psychiatric features; first‑line immunotherapies include steroids, IVIG, and plasmapheresis.

Second-line therapy roleSecond-line immunotherapy including rituximab and cyclophosphamide is used when first-line therapies fail; observational cohorts show improved odds of good outcome with second‑line therapy.

Timing importanceEarlier initiation of second‑line therapy is associated with better outcomes in large observational cohorts.

inv-143: Anti‑MDA5 dermatomyositis — Definition and clinical significance

Anti‑MDA5 dermatomyositis definitionAnti‑MDA5 dermatomyositis is a form often amyopathic with high risk of rapidly progressive interstitial lung disease and poor prognosis.

Clinical implicationCase reports suggest potential responsiveness to rituximab in anti‑MDA5–positive RP‑ILD, though evidence is limited to case series.

Consideration for usePresence of anti‑MDA5 antibodies in DM with pulmonary involvement may prompt consideration of rituximab in refractory cases per limited evidence.

inv-144: Desensitization — Pre-transplant interventions to lower anti-HLA antibodies (PRA/cPRA)

Desensitization definitionDesensitization refers to pre‑transplant interventions (eg, plasmapheresis, IVIG, rituximab, bortezomib) intended to lower anti‑HLA antibodies (PRA/cPRA) to increase transplant compatibility and reduce rejection risk.

Role of rituximabRituximab has been used as part of desensitization regimens to decrease anti‑HLA antibodies, often combined with plasmapheresis and IVIG.

cPRA guidanceDesensitization is commonly considered when calculated PRA (cPRA) exceeds 50% though approaches and outcomes vary and evidence is limited.

inv-145: ANCA-associated vasculitis (AAV) — Definition and common subtypes

AAV definitionANCA-associated vasculitis (AAV) comprises small‑vessel vasculitides including granulomatosis with polyangiitis and microscopic polyangiitis; historically treated with cyclophosphamide and glucocorticoids.

Rituximab roleRandomized trials (eg, RAVE, MAINRITSAN) demonstrate rituximab is non‑inferior for induction and superior for maintenance relapse‑free survival in many AAV contexts.

Documentation needsPrior treatment history and disease status (new vs relapsing) are relevant when considering rituximab for AAV per policy guidance.

inv-146: INCAT sensory score (ISS) — Outcome measure used in inflammatory neuropathy trials

INCAT sensory score (ISS)The INCAT sensory score (ISS) is a disability/sensory scoring instrument used as a primary outcome in inflammatory neuropathy trials (eg, anti‑MAG trials).

Use in trialsISS was the primary outcome in randomized trials assessing rituximab in anti‑MAG demyelinating neuropathy.

Interpretation cautionNegative changes in ISS in RCTs informed policy decisions deeming rituximab ineffective for the primary outcome in anti‑MAG neuropathy.

inv-147: Refractory autoimmune hepatitis (AIH) — Definition used in pilot studies

Refractory AIH definitionRefractory autoimmune hepatitis (AIH) refers to biopsy‑proven AIH not controlled by prednisone and azathioprine or intolerant to those agents, as in pilot studies of rituximab.

Evidence basisSmall pilot studies report biochemical and histologic improvement with rituximab in refractory AIH, supporting further investigation.

Documentation expectationsRequire prior failure or intolerance to standard therapy and biopsy‑proven diagnosis when considering rituximab for AIH.

inv-148: Autoimmune Limbic Encephalitis (ALE) — Definition and typical features

Autoimmune Limbic Encephalitis (ALE)ALE is immune‑mediated inflammation of the limbic system often associated with autoantibodies and presenting with seizures, memory impairment, and psychiatric symptoms.

Rituximab roleRituximab as second‑line immunotherapy has been associated with functional improvement in observational cohorts regardless of antibody status.

Treatment contextConsider rituximab after failure of first‑line therapies (steroids, IVIG, plasmapheresis) with documentation of prior therapy timing and response.

inv-149: Autoimmune Retinopathy (AIR) — Definition and diagnostic features

Autoimmune Retinopathy (AIR)AIR is a rare, potentially blinding condition with rapidly progressive vision loss, abnormal retinal electrophysiology, and positive anti‑retinal antibodies that may be monitored with ERG.

Rituximab evidenceCase series suggest rituximab may stabilize or improve visual function in some non‑paraneoplastic AIR patients unresponsive to other immunosuppression.

Monitoring recommendationRegular ERG follow‑up is recommended to monitor progression and response during rituximab therapy in AIR cases.

inv-150: Chronic immune-mediated neuropathies — Group definition and response variability

Chronic immune‑mediated neuropathies groupIncludes CIDP, autoimmune nodopathy, multifocal motor neuropathy, and anti‑MAG neuropathy; response rates to rituximab vary across subtypes.

Evidence strengthMost evidence is from case series and small studies; RCT data are limited and heterogeneous, requiring cautious interpretation.

Use contextRituximab may be considered for refractory cases or when coexisting hematologic disease is present; first‑line therapies remain IVIG and corticosteroids for many subtypes.

inv-151: Refractory disease — Definition used across studies

Refractory disease definitionRefractory disease denotes conditions not adequately controlled by glucocorticoids and at least one immunosuppressive or immunomodulatory agent (as in RIM trial where mean prior agents was 3.1).

Implication for rituximabMany off‑label and autoimmune uses of rituximab are considered primarily in refractory disease after standard therapies fail.

Documentation needPrior therapies, intolerance, and objective measures of disease activity should be documented when requesting rituximab for refractory indications.

inv-152: Inhibitors in hemophilia — Neutralizing antibodies to factor VIII/IX

Inhibitors in hemophilia definitionInhibitors are neutralizing antibodies to factor VIII or IX that reduce effectiveness of replacement therapy and complicate bleeding control.

Rituximab evidenceEvidence for rituximab in eradication of inhibitors in inherited hemophilia is limited to case reports/series; no RCTs identified in Cochrane review.

Coverage considerationRoutine use for inhibitor eradication may be considered experimental absent RCT‑level evidence; document prior therapy failures when requesting rituximab.

inv-153: Complete response (ITP, pediatric pooled analysis) — Platelet count threshold definition

Complete response (pediatric ITP)Complete response is defined as platelet count ≥ 100 × 10^9/L in pooled pediatric ITP studies.

Response definitionResponse in pediatric ITP analyses is defined as platelet count ≥ 30 × 10^9/L.

Evidence notePooled pediatric studies report complete and overall response rates after rituximab but call for RCTs for clarification of role in children.

inv-154: Response (ITP, pediatric pooled analysis) — Platelet count response definition

ITP response thresholdResponse defined as platelet count ≥ 30 × 10^9/L in pediatric pooled analyses.

Clinical contextRituximab has been used off‑label as second‑line therapy in pediatric and adult ITP with varying response durations and safety profiles.

RecommendationReserve rituximab for refractory cases or when splenectomy and other options are unsuitable; document prior therapies and response.

inv-155: Expanded Disability Status Scale (EDSS) — Neurologic disability scale used in RRMS trial entry

EDSS use in RRMS trialsExpanded Disability Status Scale (EDSS) was used as an entry/assessment scale in RRMS trials (eg, entry score ≤ 5.0 in included RCT).

Trial contextSmall RCTs in RRMS used EDSS among other measures to evaluate efficacy of rituximab on disability and relapse outcomes.

InterpretationEDSS thresholds help define trial populations but do not alone determine coverage; clinical context and prior therapies matter.

inv-156: Relapsing-Remitting Multiple Sclerosis (RRMS) — Definition and trial endpoints

RRMS definition and trial endpointsRelapsing‑remitting MS (RRMS) is characterized by relapses with recovery; trials assessed MRI gadolinium‑enhancing lesions and relapse rates over ~48 weeks.

Evidence limitsEvidence for rituximab in RRMS is limited to small RCTs showing reductions in MRI lesions and short‑term relapse rates; long‑term safety and disability effects uncertain.

PPMS caveatA large PPMS trial failed to meet its primary endpoint; subgroup signals are exploratory and not practice‑changing.

inv-157: Refractory Myasthenia Gravis — Definition for populations studied with rituximab

Refractory Myasthenia Gravis definitionRefractory MG denotes steroid‑dependent or unresponsive disease to conventional therapies; many rituximab studies focus on this population including AChR and MuSK subtypes.

Evidence summaryObservational studies and meta‑analyses report clinical improvement and steroid‑sparing effects with rituximab in refractory MG, especially MuSK‑positive patients.

Treatment expectationsDocument prior therapy failures and antibody subtype when considering rituximab; RCT data remain limited and most evidence is observational.

Clinical Background and Evidence Context

Rituximab is a chimeric anti‑CD20 monoclonal antibody directed against B cells and is used across a broad range of B‑cell hematologic malignancies and select autoimmune conditions. The policy covers multiple FDA‑approved products and biosimilars and specifies indication‑ and product‑specific dosing and administration requirements (including IV infusion for most products and subcutaneous Rituxan Hycela after a prior IV dose). Clinical coverage decisions reflect varying levels of evidence across oncologic and autoimmune indications and require precertification and appropriate documentation for authorization.

Policy Revision History

1999-01-04effective_date

Policy originally became effective.

2011-01-01FDA/maintenance_update_reference

FDA approval and maintenance guidance (PRIMA trial) recognized for rituximab maintenance in follicular lymphoma per background and references; incorporated into policy's coverage context.

2019-12-17biosimilar_approval_update

FDA approval of Truxima (rituximab-abbs) noted in background and compendial uses; biosimilars described in policy.

2024-03-04last_reviewLatest

Policy last reviewed and updated on 2024-03-04 (document-level last review date).

Policy Summary

PayerAetna

PolicyRituximab (including biosimilars and hyaluronidase formulation)

Policy CodePolicy 0314

Change TypeNo material change

Effective DateJan 4, 1999

Next Review DateJun 27, 2024

Key ActionPrecertification of rituximab (all listed brands/formulations) is required for applicable commercial plan designs.

SourceLink

On This Page